Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation. Participants were prioritised based on vulnerabilities compromising oral pre-exposure prophylaxis (PrEP), such as poor adherence, comorbidities and behavioural barriers. Adherence to injections exceeded 95%, tolerability was favourable and only 1.5% discontinued for drug-related reasons. These findings demonstrate the feasibility of CAB-LA in European clinical services and support its use in specific populations.
Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025 / D. Moschese, R. Esvan, C. Fusetti, V. Barchi, M.V. Cossu, A. Giacinta, S. Lazzarin, G. Terracini, F. Caruso, G. Micheli, D. Maddalena, G. Del Duca, F. Petri, G. Frate, M. Matone, D. Farinacci, A. Giacomelli, P. Faccendini, D. Visigalli, S. Passacantilli, A. Riva, A. Antinori, A. Gori, V. Mazzotta. - In: EUROSURVEILLANCE. - ISSN 1560-7917. - 30:39(2025 Oct 02), pp. 1-6. [10.2807/1560-7917.ES.2025.30.39.2500739]
Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025
D. Maddalena;F. Petri;M. Matone;A. Giacomelli;D. Visigalli;A. Riva;A. GoriPenultimo
;
2025
Abstract
Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation. Participants were prioritised based on vulnerabilities compromising oral pre-exposure prophylaxis (PrEP), such as poor adherence, comorbidities and behavioural barriers. Adherence to injections exceeded 95%, tolerability was favourable and only 1.5% discontinued for drug-related reasons. These findings demonstrate the feasibility of CAB-LA in European clinical services and support its use in specific populations.
| File | Dimensione | Formato | |
|---|---|---|---|
|
eurosurv-30-39-2.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Licenza:
Creative commons
Dimensione
268.52 kB
Formato
Adobe PDF
|
268.52 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
